ABT’s recent stock price performance
On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share. The stock was trading at a 52-week low of $42.31 on April 17, 2017. On January 25, 2018, the company was trading at a 52-week high of $64.60 following a strong 4Q17 and fiscal 2017 earnings release on January 24—despite company-specific as well as broader market headwinds in 2017. For more, see Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Successful key product launches (see Abbott Stock Rides High on Recent Product Approvals), strategic acquisitions and divestitures, and an attractive product pipeline have positioned Abbott Laboratories as attractive over the long term. Currently, ABT stock is trading higher than its 50-day moving average of $59.62 as well as its 200-day moving average of $55.01.
ABT stock registered returns of ~1.5% over the last month. On a YTD (year-to-date) basis, ABT stock has risen ~5.4%. Over the last six months, ABT has provided a return of 23.5%. The stock’s one-year return is ~34.6% as of February 19.
Peer and market comparisons
As of February 19, peers Becton Dickinson (BDX), Boston Scientific (BSX), and Baxter International (BAX) have registered stock price gains of ~23.2%, ~7.1%, and 33.4%, respectively, over the last year.
For the same period, the S&P 500 Index and the iShares US Medical Devices (IHI) have grown ~16.2% and ~24.5%, respectively. ABT stock has largely outperformed its peers, the US medical devices sector’s average returns, as well as the broader market performance over the last year.